Mechanism of Action - The Beta Blockade
- Receptor Antagonism: Competitively block β1-adrenergic receptors in cardiac tissue (SA and AV nodes, myocytes), antagonizing catecholamine effects.
- Cellular Cascade: This blockade inhibits the Gs-protein pathway, leading to ↓ adenylyl cyclase activity and subsequent ↓ intracellular cAMP.
- Electrophysiological Impact:
- SA Node: Decreases the slope of Phase 4 depolarization by reducing the $I_f$ "funny" current, thus ↓ heart rate.
- AV Node: Slows conduction and increases refractoriness, prolonging the PR interval.
- Suppresses EADs/DADs and abnormal automaticity.
⭐ Beta-blockers are uniquely effective in terminating tachyarrhythmias caused by excessive sympathetic stimulation (e.g., post-MI, exercise, thyrotoxicosis).
Pharmacokinetics - In, Around, and Out
-
Absorption & Distribution
- Lipid solubility dictates CNS penetration.
- High solubility (Propranolol, Metoprolol) → Crosses BBB → CNS side effects.
- Low solubility (Atenolol, Nadolol) → Fewer CNS effects.
-
Metabolism & Elimination
-
Half-Lives
- Shortest: Esmolol (IV) ~10 minutes.
- Longest: Nadolol ~24 hours (renal excretion).
⭐ Esmolol is metabolized by RBC esterases, giving it a very short duration of action. This makes it perfect for titrating β-blockade in acute, emergency settings (e.g., aortic dissection, supraventricular tachycardia).
Clinical Use & Side Effects - Friend and Foe
Clinical Use ("Friend"):
- Cardiovascular: Post-MI, stable angina, HTN, stable HF (↓ mortality).
- Arrhythmias: Rate control in atrial fibrillation/flutter, SVT.
- Other: Hyperthyroidism (symptom control), glaucoma, performance anxiety, migraine prophylaxis.
Side Effects ("Foe"):
- Cardiovascular: Bradycardia, AV block, hypotension, worsening acute decompensated HF.
- Pulmonary: Bronchoconstriction (non-selective agents).
- Metabolic: Can mask hypoglycemia symptoms (e.g., tachycardia).
- CNS: Fatigue, depression, sexual dysfunction.
- ⚠️ Warning: Avoid abrupt cessation (rebound tachycardia/HTN).
⭐ In cocaine toxicity, avoid β-blockers due to risk of unopposed α-adrenergic stimulation, leading to extreme hypertension.
The Beta Blocker Lineup - Know Your Players
- Mechanism: Block β-adrenergic receptors, ↓ cAMP → ↓ Ca²⁺ currents. Suppress abnormal pacemaker activity & ↓ AV node conduction.
- 📌 Mnemonic: A to M names (Atenolol, Esmolol, Metoprolol) are β₁-selective; N to Z (Nadolol, Propranolol) are Non-selective.
| Agent | Selectivity | Key Features |
|---|---|---|
| Metoprolol | β₁ > β₂ | Commonly used post-MI. |
| Propranolol | β₁ = β₂ | High lipid solubility, crosses BBB (performance anxiety). |
| Esmolol | β₁ > β₂ | IV only, very short-acting (t½ ≈ 9 min). |
| Carvedilol | α₁, β₁, β₂ | Benefits in heart failure; antioxidant properties. |
| Labetalol | α₁, β₁, β₂ | Safe in pregnancy; used for hypertensive emergencies. |
High‑Yield Points - ⚡ Biggest Takeaways
β-blockers decrease cAMP and Ca²⁺ currents, primarily at the SA and AV nodes. They ↓ the slope of phase 4 depolarization, slowing conduction and heart rate. The key EKG finding is an increased PR interval. Primarily used for rate control in atrial fibrillation/flutter and to prevent post-MI ventricular arrhythmias. Major risks include heart block, severe bradycardia, and bronchospasm (non-selective agents).
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
